Global Medical REIT (NYSE: GMRE) is a small-cap equity REIT focused on net-leased healthcare real estate, offering a high dividend yield of ~9%. GMRE owns a diversified portfolio of 191 medical facilities (5.2 million square feet) across 36 states, leased to physician groups and regional health systems. The REIT's strategy targets specialized healthcare assets (medical office buildings, inpatient rehab hospitals, etc.) in secondary markets at above-average cap rates, supporting generous dividends. Recent initiatives – including a new CEO appointment in 2025 and refinancing of near-term debt – have improved GMRE's financial footing. However, rising interest rates and past tenant credit issues have challenged growth, prompting a dividend reduction in 2025 to strengthen coverage.
Recommendation: Buy (Moderate Risk). GMRE offers an attractive 9.2% yield that appears sustainable (AFFO payout ~66% post-cut), and the stock trades at ~7.4× forward AFFO – a discount to peer medical REITs. We assign an overall quality grade of , reflecting a solid portfolio and improved balance sheet tempered by its small size and niche focus.
We advise accumulating shares on dips around $30, with a 12-month price target of $40 (20% upside plus dividend) and a longer-term target of $45-$50 if interest rate pressures ease. A stop-loss near $26 is recommended to limit downside. Key catalysts include upcoming earnings (Q4'25 in Feb 2026) confirming guidance, potential share buybacks, and any successful lease-up of a previously vacant hospital asset. This REIT is best suited for income-focused investors willing to accept moderate volatility for a high yield backed by essential healthcare real estate.
Global Medical REIT is an equity REIT specializing in net-leased healthcare properties. It predominantly acquires purpose-built medical facilities – including medical office buildings (MOBs), inpatient rehab hospitals (IRFs), surgical centers, and specialty clinics – and leases them to clinical operators under long-term triple-net or absolute-net leases. The portfolio is broadly diversified across healthcare sectors (71.5% of rent from MOBs, 17.4% from IRFs, remainder from hospitals/other), aligning with favorable demographics (aging population) and the industry trend toward outpatient care in local markets.
As of Q3 2025, GMRE owns 191 properties totaling ~5.2 million leasable sq. ft. and generating $118.4 million in annualized base rent (ABR). Properties are 95.2% leased, with a weighted average lease term (WALT) of 5.3 years and average annual rent escalations of ~2.1%. The REIT targets secondary markets where cap rates are higher; its largest geographic exposures are Texas (16.2% of ABR) and Florida (11.9%), with no other state above ~9%. GMRE's tenant base is diverse, comprised of 300+ tenants primarily consisting of regional health systems and specialty physician groups – no single tenant accounts for more than ~7% of rent.
GMRE's strategy is to provide sale-leaseback and growth capital to healthcare operators by acquiring their real estate and leasing it back on a long-term, triple-net basis. This yields attractive cap rates (~8–9%) relative to core office properties, supporting higher cash yields to investors. Management emphasizes "mission-critical" facilities – e.g. community hospitals, ambulatory surgery centers, and multi-specialty clinics – often affiliated with dominant health systems in a region. These tend to have high tenant retention and strong rent coverage (GMRE's portfolio rent coverage is 4.4× EBITDA on average), helping ensure steady rental income for dividend payouts. The REIT was externally managed at inception but completed an internalization of management in 2021, aligning management with shareholders.
Founded in 2014 and IPO'd in mid-2016, GMRE has rapidly grown via acquisitions from an initial ~$250 million portfolio to $1.5 billion in gross real estate assets today. The company's long-time CEO and founder, Jeffrey Busch, led this expansion and remains Chairman. In June 2025, GMRE implemented a planned leadership transition: Mark Decker Jr. was appointed CEO and President. Decker Jr. brings extensive REIT experience (former CEO of Centerspace and a real estate investment banker) and is tasked with refining GMRE's strategic direction. Under his fresh perspective, GMRE is focusing on portfolio optimization and capital allocation to maximize shareholder value. The CFO, Robert Kiernan, has 30+ years of financial experience and has been instrumental in GMRE's capital markets activities. Insider ownership is meaningful – CEO Decker and CFO Kiernan recently bought shares on the open market (10,000 and 3,000 shares respectively in Nov 2025) as a signal of confidence. Overall, GMRE's governance features a mostly independent board (8 members) and an insider ownership of ~5-10% (including Operating Partnership units), providing alignment with shareholders.
In September 2025, GMRE enacted a 1-for-5 reverse stock split to improve its stock price and comparability (all per-share figures hereafter reflect the split). That same month, the company refinanced and upsized its credit facility, extending its $400M revolver maturity to 2029 and its $350M term loan into three tranches maturing 2029–2031. This proactive refinancing significantly alleviated near-term debt pressure (prior weighted average maturity was only 1.3 years). Additionally, GMRE trimmed its quarterly common dividend by ~27% in mid-2025 (from $1.05 to $0.75 post-split) to strengthen retained cash flow for reinvestment and deleveraging. This tough decision, along with the new leadership and financial moves, position GMRE to navigate the high interest rate environment with a more sustainable payout and improved liquidity. Management reaffirmed full-year 2025 AFFO guidance of $4.50–$4.60 per share (after the split), indicating stability in operating performance despite macroeconomic headwinds.
| Portfolio Metrics (Q3 2025) | Value |
|---|---|
| Property Type Focus | Net-Lease Healthcare (MOBs, IRFs, Hospitals) |
| Properties Owned | 191 buildings in 36 states |
| Leasable Square Feet | 5.2 million sqft (95.2% leased) |
| Top States (% of ABR) | TX 16.2%, FL 11.9%, OH 8.8%, PA 6.6% |
| Annualized Base Rent (ABR) | $118.4 million (triple/absolute net leases ~91% of ABR) |
| Major Tenants | ~315 tenants; largest <7.5% of ABR (LifePoint Health) |
| Weighted Avg Lease Term | 5.3 years; WALT with 2.1% avg. annual escalations |
| Rent Coverage (Tenant EBITDARM) | 4.4× portfolio average |
| 2025E FFO / AFFO per Share (guidance) | FFO ~$3.00; AFFO ~$4.55 (post-split) |
| Annual Dividend per Share (Common) | $3.00 (2025 forward, paid quarterly at $0.75) |
| Dividend Yield (Current) | ~9.2% (at $33 stock price) |
| Market Capitalization (Common Equity) | ~$0.45 billion (13.4M shares × ~$33) |
| Total Debt Outstanding | $710 million (47% leverage by assets) |
| Credit Facility Availability | $171 million undrawn (post-refinancing) |
| Credit Ratings | Not rated (unsecured debt via bank facility) |
GMRE's value proposition lies in its durable rental income from essential healthcare facilities. The continued shift of healthcare delivery to outpatient settings (e.g., surgery centers, clinics) provides a structural tailwind for demand in the types of properties GMRE owns. At the same time, higher interest rates have increased the REIT's cost of capital and pressured its stock price, necessitating prudent capital management. GMRE's recent dividend cut and debt refinancings indicate management's commitment to maintain balance sheet strength and dividend reliability. Going forward, the REIT will emphasize organic growth (rent escalators ~2% and maintaining high occupancy) and selective acquisitions funded through joint ventures or retained cash, rather than dilutive equity issuance. With a new CEO focused on portfolio optimization and an insider team signaling confidence via share purchases, GMRE is positioning itself for a transition from a rapid-growth small cap to a more disciplined, income-oriented mid-cap REIT.
GMRE's portfolio is well-diversified across property types, geographies, and tenants, though it carries the typical characteristics of a net-lease healthcare REIT (single-tenant concentration at the property level and medium lease terms). Below we present a detailed breakdown:
Table 2.1 summarizes GMRE's properties by type and region. Notably, medical office buildings (MOBs) contribute ~72% of annual rent and ~77% of leasable area – this includes outpatient clinics, surgical centers, imaging labs, and urgent care facilities. Inpatient rehabilitation facilities (IRFs) (post-acute rehab hospitals) comprise 17% of rent, reflecting GMRE's niche focus on smaller specialty hospitals. The remaining rent comes from a handful of acute-care and specialty hospitals (~8.6% ABR) and healthcare office facilities (~2.5% ABR). This mix skews more toward hospital/acute care exposure than pure-play MOB REITs like Physicians Realty, but it is balanced by the fact that most hospital tenants are under net leases and many are backed by large health systems (as described below). Importantly, GMRE's assets are predominantly net-leased: ~91% of ABR comes from triple-net or absolute-net leases where tenants cover property expenses, which insulates GMRE's NOI from inflation in operating costs.
| Property Type | Leasable SF | % of SF | ABR ($M) | % of ABR | Key Examples |
|---|---|---|---|---|---|
| Medical Office Buildings (MOB) | 3,649,000 | 76.7% | $78.7 | 71.5% | Multi-specialty clinics, surgery centers |
| Inpatient Rehab Facilities (IRF) | 501,000 | 10.5% | $19.1 | 17.4% | Rehabilitation hospitals (post-acute) |
| Healthcare Admin/Office | 138,000 | 2.9% | $2.8 | 2.5% | Medical corporate offices, clinics |
| Specialty/Other Healthcare | 469,000 | 9.9% | $9.4 | 8.6% | Acute-care hospital ($2.6M), LTAC hospital ($2.6M), Surgical hospital ($1.5M), Behavioral hospital ($1.4M), etc. |
| Total Portfolio | 4,756,000 | 100.0% | $110.0 | 100.0% | (ABR as of Dec 31, 2024; excludes JV assets) |
| Top Regions (States) | Leasable SF | % of SF | ABR ($M) | % of ABR | Notes |
|---|---|---|---|---|---|
| Texas (TX) | 709,000 | 14.9% | $17.8 | 16.2% | Largest exposure (multiple assets) |
| Florida (FL) | 589,000 | 12.4% | $13.1 | 11.9% | Strong retiree/tourism markets |
| Ohio (OH) | 419,000 | 8.8% | $9.6 | 8.8% | Includes Memorial Health's region |
| Pennsylvania (PA) | 286,000 | 6.0% | $7.3 | 6.6% | — |
| Illinois (IL) | 309,000 | 6.5% | $7.0 | 6.3% | — |
| Arizona (AZ) | 184,000 | 3.9% | $6.7 | 6.1% | Growing Sunbelt presence |
| Michigan (MI) | 306,000 | 6.4% | $5.8 | 5.3% | — |
| Other (30 states) | 1,954,000 | 41.1% | $42.8 | 38.8% | No other single state >5% ABR |
| Total Portfolio | 4,756,000 | 100% | $110.0 | 100% | (Data as of Dec 31, 2024) |
GMRE's rental income is well-distributed: the top 10 tenants account for roughly one-third of ABR (approximately 35%), and no tenant contributes more than ~7% individually. Table 2.2 lists the largest tenants as of Q3 2025 and their rent contributions:
| Tenant (Operator) | % of ABR | Tenant Description & Credit |
|---|---|---|
| LifePoint Health | 6.8% | Large for-profit hospital system (60+ hospitals nationwide). Privately owned, mid-tier credit. GMRE leases multiple community hospitals to LifePoint. |
| Encompass Health (NYSE:EHC) | 6.3% | Nation's largest inpatient rehab hospital operator (150+ rehab hospitals). Investment-grade rated; GMRE's IRF facilities are leased to Encompass. |
| Memorial Health System | 5.0% | Not-for-profit regional health system in Ohio (Marietta Memorial Hospital and affiliates). Strong local market presence. |
| Trinity Health | 4.4% | Major Catholic not-for-profit health system (93 hospitals across 26 states), rated AA- by Moody's. GMRE leases MOBs affiliated with Trinity (e.g. MercyOne clinics). |
| TeamHealth | 2.9% | Leading physician staffing and practice management company (emergency medicine, hospitalist services). Not typically a real estate tenant, but GMRE has a few facilities leased to TeamHealth for clinical operations. |
| Tenet Healthcare (NYSE:THC) | 2.9% | Large for-profit hospital system (65 hospitals, 450+ ambulatory facilities) based in Dallas. Tenet (Moody's B+) is an anchor tenant in some GMRE assets (including surgery centers via its USPI subsidiary). |
| Carrus Health | ~2.6% (est.) | Private operator of long-term acute care and rehab hospitals in Texas/Oklahoma. Focused on post-acute and hospice care. Carrus leases two specialty hospitals in GMRE's portfolio (cap rate ~8–9%). |
| CHRISTUS Health | ~2.4% (est.) | A+ rated not-for-profit health system (60+ hospitals in TX/LA/NM and Latin America). In 2024, CHRISTUS signed a new 15-year lease for GMRE's Beaumont, TX medical center, replacing prior tenant Steward Health. |
| HCA Healthcare (NYSE:HCA) | ~2% (est.) | Largest for-profit hospital chain in the U.S. (180+ hospitals). While not a top 5 tenant, HCA or its affiliates appear as tenants in a few GMRE properties, underscoring the REIT's relationships with big health systems. |
| Pipeline Health (Heights Healthcare) | ~2% (est.) | A regional hospital operator (Pipeline) that filed Chapter 11 in 2022; GMRE's only acute-care hospital was occupied by Pipeline. That hospital was sold to Heights Healthcare in late 2023. A new lease or restructured terms with the incoming operator could restore this rent. |
Source: Company filings and supplemental data. ABR percentages as of Q3 2025 (GMRE "Key Tenants" profile).
The tenant roster reveals a mix of strong credits and some weaker operators, typical for a healthcare REIT: for example, health systems like Trinity and CHRISTUS (rated A/A+) bring stability, while smaller private operators (Carrus, certain behavioral hospital tenants) are lower credit quality. Positively, the top three tenants contribute only ~19% of rent, which is low concentration relative to some peers (by contrast, Medical Properties Trust's top tenant was ~25%+ of rent). GMRE's focus on net leases to health systems provides a measure of safety – many facilities are effectively "outsourced" real estate for major hospital networks. For instance, the five-property Trinity/MercyOne portfolio GMRE acquired in 2025 deepened its ties with a AA- rated system. The downside is that single-tenant properties can go dark if an operator fails. GMRE experienced this with Steward Health Care (a tenant for one hospital, ~2% ABR) which went bankrupt in 2024, but impressively, GMRE re-leased the facility to CHRISTUS Health within months. This responsiveness demonstrates management's asset management capability and the underlying demand for well-located healthcare facilities.
GMRE's lease expiration schedule is reasonably staggered, albeit with a notable concentration in the year 2029. As shown in Table 2.3, no single year through 2028 accounts for more than ~11% of ABR, but 2029 has 17.3% of rent expiring (the largest rollover exposure). This 2029 "hump" likely relates to a batch of deals done in 2019 with 10-year initial terms. Beyond 2029, another ~15% of ABR expires in 2034+ ("Thereafter"). The weighted average lease term (WALT) stands at ~5.3 years as of Q3 2025, a bit shorter than that of larger MOB-focused REITs (many have 6–7 year WALTs). However, GMRE has demonstrated a solid track record of renewals: for instance, recent leasing in the Trinity/MercyOne portfolio achieved 99% retention on 2024–25 expirations, with no GMRE-funded tenant improvements required.
| Year Lease Expires | ABR Expiring | % of Total ABR | # of Leases | Leased SF (000s) |
|---|---|---|---|---|
| 2025 | $9.86 million | 9.0% | 63 leases | 508 SF |
| 2026 | $10.56 million | 9.6% | 72 leases | 497 SF |
| 2027 | $12.20 million | 11.1% | 50 leases | 470 SF |
| 2028 | $7.28 million | 6.6% | 36 leases | 262 SF |
| 2029 | $19.08 million | 17.3% | 60 leases | 770 SF |
| 2030 | $12.21 million | 11.1% | 39 leases | 493 SF |
| 2031 | $7.83 million | 7.1% | 22 leases | 378 SF |
| 2032 | $2.06 million | 1.9% | 6 leases | 65 SF |
| 2033 | $4.77 million | 4.3% | 18 leases | 180 SF |
| 2034 | $7.34 million | 6.7% | 12 leases | 235 SF |
| 2035 and beyond | $16.82 million | 15.3% | 25 leases | 729 SF |
| Total | $110.0 million | 100.0% | 403 leases | 4,586 SF (96.4% leased) |
Note: Approximately 3.6% of GMRE's total portfolio square footage is currently vacant (170,185 SF). This vacancy is spread across a few properties; management is actively marketing these spaces or re-tenanting them.
GMRE's assets are generally "middle-market" healthcare facilities: they are not the huge trophy medical centers in gateway cities (which are dominated by larger REITs), but rather community-focused facilities in secondary markets. This niche can be advantageous – less institutional competition for acquisitions and higher going-in yields – but also means GMRE's properties may have fewer alternative uses and rely on the success of a specific tenant or local healthcare market. Nevertheless, the portfolio quality appears solid: occupancy is high, rent collection has been near 100% (even through COVID-19, GMRE had minimal deferrals), and same-store NOI is growing (~2.7% YoY same-store cash NOI growth in Q3 2025).
GMRE does have pockets of concentration investors should note:
In conclusion, GMRE's portfolio exhibits good diversification and resilience for a REIT of its size. Its assets occupy a competitive niche in the healthcare real estate spectrum – generally high cap rate, community-based facilities with credible tenants. The portfolio's performance (mid-90s occupancy, ~3% SS NOI growth, 99% rent collections) attests to its quality.
Global Medical REIT possesses several competitive advantages that underpin its investment thesis:
GMRE has built a broad-based portfolio with no outsized single-tenant or geographic risk. Its largest tenant (LifePoint) is only ~7% of rent, and the top three make up ~19% – a low concentration relative to many net-lease REITs. Likewise, the properties are spread across 36 states, with the biggest state (Texas) at 16% of ABR and no other above 12%. This diversification means GMRE's cash flows are not overly reliant on any one hospital system or market. Occupancy stands at a robust 95+% (95.2% in Q3 2025), reflecting strong demand for its facilities. Notably, GMRE's same-store cash NOI grew +2.7% year-over-year in Q3 2025, indicating organic growth from rent escalations and stable occupancy.
The REIT's cash flows benefit from long-duration leases and contractual rent bumps. The weighted average lease term is ~5.3 years, and many leases have options extending into the 2030s. Annual rent escalations average ~2.1% across the portfolio, which provides steady internal growth that compounds over time. These escalators help offset inflation and contribute to same-store NOI increases. Importantly, 91% of ABR comes from triple-net or absolute-net leases, meaning tenants bear property-level expenses (taxes, insurance, maintenance). This structure insulates GMRE's margins against expense inflation – a notable advantage in the current high-inflation environment.
GMRE's tenants, on average, exhibit healthy financial coverage of their rent obligations. The portfolio's weighted average EBITDARM rent coverage is 4.4× (i.e., tenants' earnings before rent are 4.4 times their rent payments). This is a comfortable cushion, suggesting that most tenants can withstand business fluctuations and still pay rent. A significant portion of GMRE's rent comes from tenants affiliated with major health systems: 89% of ABR is derived from health system or other affiliated healthcare groups. This includes tenants like Trinity Health (AA- rated), CHRISTUS Health (A+), and Encompass Health (BBB-).
GMRE's strategy of targeting secondary market healthcare assets yields higher cap rates (often 8–9% initial yields) than investments in primary markets. This is a competitive advantage in driving FFO/AFFO growth and supporting a high dividend. For instance, GMRE's May 2025 portfolio acquisition (five properties) was done at a 9.1% cap rate (Year 1). These cap rates are well above the company's cost of long-term debt (~4–5%) and even its equity yield (currently ~9% yield on stock), making deals potentially accretive.
GMRE has recently taken significant steps to shore up its balance sheet, which enhance its financial stability. In October 2025, management executed an amended and restated credit facility extending debt maturities and removing near-term refinancing risk. The $400M revolving credit's maturity was pushed to 2029 (with extensions to 2030) and the $350M term loan was split into tranches due 2029–2031. As a result, GMRE's weighted average debt maturity improved from ~1.3 years to 4.4 years post-refinancing. The refinancing also hedged interest rates on all new term loan tranches. Additionally, in August 2025 GMRE's board authorized a $50 million stock repurchase program.
GMRE's leadership brings substantial healthcare real estate know-how and capital markets expertise. New CEO Mark Decker Jr. previously led a public REIT transformation and spent two decades in REIT investment banking. The fact that insiders like Decker and CFO Robert Kiernan have been buying shares (together purchasing ~$0.42 million of stock in November 2025 at ~$32/share) is a strong signal of insider confidence in GMRE's prospects. It aligns management's interests with shareholders' and suggests they view the stock as undervalued.
The healthcare real estate sector benefits from non-cyclical demand drivers. GMRE's properties cater to fundamental healthcare needs – e.g., rehabilitation services, outpatient surgeries, diagnostics – which are in growing demand due to the aging population and increased chronic disease prevalence. The U.S. population aged 65+ is expanding rapidly, fueling healthcare utilization in GMRE's primary segments. Moreover, the decentralization of healthcare delivery (moving procedures out of big hospitals into local outpatient centers) plays directly into GMRE's strategy. This defensive characteristic is a key strength for GMRE as an investment.
Despite its strengths, Global Medical REIT faces certain weaknesses and challenges that could impede its performance relative to peers:
GMRE's market capitalization (≈$0.45 billion) is a fraction of major healthcare REITs, which limits its economies of scale and bargaining power. Its small-cap status also contributes to a higher cost of equity – the stock's dividend yield is ~9.2%, significantly above big peers like Physicians Realty (~6.8%) or Healthcare Realty (~7.4%). This implies the market demands a higher risk premium for GMRE. As a result, raising equity capital for growth is expensive/dilutive at current pricing. GMRE's smaller asset base (191 properties) also means less diversification by asset count and higher relative exposure to any single asset's performance.
GMRE's leverage, measured on a market basis, is relatively high. Net debt to enterprise value is roughly ~60% at the current stock price (debt $710M vs equity ~$470M) – higher than many peers (Physicians Realty's is ~28%, Healthcare Realty ~38%). Even by assets, GMRE carries debt at ~47% of total gross assets. While not unusual for a smaller REIT, this is on the higher side of the healthcare REIT range and leaves less buffer for downturns. The company's interest coverage ratio (EBITDAre to interest) was a modest 2.7× as of Q3 2025, indicating fairly tight coverage.
The vast majority of GMRE's properties are single-tenant, net-leased assets. This structure, while providing steady income when occupied, poses a binary occupancy risk. If a tenant vacates at lease expiration or defaults, the entire property's cash flow goes to zero, and re-leasing can be challenging, especially for specialized healthcare space. GMRE's Aurora, IL health administration building went vacant in 2023, leading to a $6.3M impairment charge in Q3 2025. Similarly, the Beaumont, TX hospital saw its tenant (Steward) reject the lease in bankruptcy, requiring a scramble to find a replacement.
While GMRE's leases have escalators, its FFO/AFFO per share growth has been relatively sluggish or even negative in recent years. From 2022 to 2024, GMRE's AFFO per share actually declined (from $0.98 to $0.89 pre-split, i.e. $4.90 to $4.45 post-split). FFO per share saw a similar drop. This indicates that GMRE hasn't achieved meaningful per-share growth, due in part to equity issuance and rising interest expense outpacing the contribution of acquisitions.
Despite a generally strong tenant roster, GMRE does have exposure to some weaker credits that larger REITs often avoid. For example, Pipeline Health (a distressed operator) was a tenant until its bankruptcy, and GMRE still awaits full stabilization of that asset under new management. GMRE does not have an investment-grade credit rating, which implies its tenant base on average is below investment-grade.
GMRE's historical growth has been heavily acquisition-driven. That growth engine has stalled in the current environment. With the stock trading at a high cost of equity and interest rates up, GMRE has dramatically slowed acquisitions (only ~$70M acquired in first nine months of 2025, versus $200M+ in some prior years). If conditions remain unfavorable, GMRE may face a period of flat portfolio growth.
GMRE's dividend cut in mid-2025, while ultimately prudent, represents a setback in its track record as an income investment. The company had previously maintained or slightly raised its dividend since IPO but was forced to reduce it ~27% to preserve cash. This indicates that prior management perhaps stretched the payout beyond what earnings growth could support. The cut likely rattled income-focused investors and may constrain GMRE's investor base.
Global Medical REIT faces several risks that could materially affect its financial performance and stock valuation. We categorize the key risks into sector-specific, company-specific, and macroeconomic:
GMRE has hedged most of its variable-rate debt, maintaining interest coverage above 2.5×. It monitors tenant financial health and often secures guarantees from stronger entities. The diversified portfolio means even a large tenant issue affects <7% of revenue. Finally, GMRE's retained cash (post dividend-cut) and $171M liquidity provide a buffer to handle unexpected vacancies or funding needs.
GMRE operates within the healthcare REIT sector, where it competes for both properties and investors with other companies focused on medical and healthcare real estate.
GMRE's closest comparables are other U.S. equity REITs with portfolios of healthcare properties, particularly those emphasizing medical office buildings or net-leased healthcare facilities. Notable peers include:
| Metric (2025E or latest) | GMRE | DOC | HR | CHCT | MPW |
|---|---|---|---|---|---|
| Portfolio Focus | Net-leased MOBs & hospitals (secondary mkts) | On-campus/outpatient MOBs (affiliated) | Multi-tenant MOBs (mostly on-campus) | Net-leased healthcare (non-urban clinics, hospitals) | Net-leased acute care hospitals (global) |
| Property Count | 191 | 290 (approx.) | 700+ | 200 | 444 (incl. JV) |
| Occupancy (Q3 2025) | 95.2% | ~95-96% | ~91.5% (record high) | 96% (leased) | ~99% |
| Top 3 Tenant Concentration | 19% ABR | ~15% | ~13% | >30% | ~32% |
| Weighted Lease Term | 5.3 yrs | ~6.5 yrs | ~7.0 yrs | ~10 yrs | ~17.6 yrs |
| P/FFO Multiple | ~7.4× | ~12× | ~10× | ~8× | ~5-6× |
| Dividend Yield | 9.2% | 6.8% | 7.3% | 13.5% | ~6.0% |
| Dividend Payout (AFFO) | ~66% | ~85% | ~73% | ~102% (unsustainable) | ~30% |
| Credit Rating | None (unrated) | BBB/Baa2 (IG) | BBB/Baa2 (IG) | None (unrated) | BB+/Ba1 |
Relative Portfolio Quality: GMRE's assets are generally secondary market, single-tenant facilities, whereas DOC and HR own more institutional-grade, on-campus MOBs in larger cities. This means DOC/HR portfolios are often perceived as higher quality/lower risk (reflected in their lower yields and higher multiples). GMRE's properties yield higher cap rates but might also have higher tenant dependence.
Diversification & Tenant Concentration: GMRE is more diversified by tenant than MPW (which historically had very high tenant concentration). This is a competitive strength for GMRE. Versus CHCT, GMRE is actually less concentrated in tenants; CHCT had two tenants each at ~10%+ of revenue, which caused big issues in 2025.
Financial Metrics: GMRE's leverage is higher than DOC/HR (who enjoy investment-grade balance sheets). GMRE's FFO multiple (~7x) is far below DOC (~12x) and HR (~10x), indicating the market prices GMRE's risk higher.
Competitive Advantages vs Peers:
GMRE's growth will derive from a combination of organic (internal) growth and external (acquisitive or strategic) growth.
For 2024–2026, the base internal growth for GMRE is around 2-3% annually (from rent escalations and high occupancy). AFFO per share could grow a bit more if interest costs stabilize. The upside to base growth will come from external moves such as acquisitions or share buybacks.
For 2025, management's AFFO/share guidance of $4.50-$4.60 implies roughly 0% to +2% growth over 2024's ~$4.45 AFFO. Over a 5-year horizon, if macro conditions normalize (interest rates ease slightly), GMRE could resume a mid-single-digit growth trajectory with AFFO per share potentially growing ~4-6% annually.
Global Medical REIT is covered by a moderate number of Wall Street analysts, primarily from smaller and mid-sized investment banks with REIT specializations. According to the company's investor relations, at least 8 analysts currently cover GMRE.
| Analyst (Firm) | Rating | Price Target | Date | Thesis Highlights |
|---|---|---|---|---|
| Wes Golladay (Baird) | Neutral | $41.00 | Nov 11, 2025 | Raised target to $41, reflecting improved visibility after refinancing. Acknowledges attractive 9% yield and better balance sheet but notes limited near-term growth. |
| Aaron Hecht (JMP Securities) | Market Outperform | $40.00 | Oct 13, 2025 | Upgraded to Outperform. Turned bullish post Q3 results and CEO transition, citing "excellent refinancing" outcomes. Believes dividend is sustainable after the cut. |
| Juan Sanabria (BMO Capital Mkts) | Market Perform | $32.00 (est.) | Sep 2025 | Maintains Hold stance. Cautious view focuses on higher leverage and small-cap risks, offset by strong healthcare real estate fundamentals. |
| Bryan Maher (B. Riley Securities) | Sell | $10.00 | May 13, 2024 | Most bearish view on Street. Argued high payout and tenant issues posed big risks. Has not updated since dividend cut and refinancing. |
| Barry Oxford (Colliers Securities) | Buy | $38.00 (est.) | Aug 2025 | Positive on small-cap REITs. Praised GMRE's move to internalize management and cut dividend as "setting the stage for future growth". |
| Merrill Ross (Compass Point) | Neutral | $30.00 (est.) | July 2025 | Noted the cut was necessary and positive, but GMRE still needs to prove AFFO stabilization. |
| Robert Stevenson (Janney) | Buy | $36.00 (est.) | June 2025 | Upgraded after CEO change, viewing it as a catalyst. Sees Mark Decker Jr.'s strategic vision potentially unlocking value. |
| Austin Wurschmidt (KeyBanc) | Sector Weight | NA | Nov 2025 | Noted "improving fundamentals but balanced by leverage". Appreciates execution on re-leasing but remains cautious until AFFO growth resumes. |
The consensus rating skews slightly bullish: out of ~6 analysts contributing to consensus, there are about 3 Buys, 3 Holds, and 0 Sells. This yields a consensus rating around "Buy/Overweight". The highest target is $41 (Baird) and the lowest is effectively around $10 (old B. Riley), but excluding that outlier, the low among active coverage is probably $30. Thus, the realistic consensus target range is ~$30–$40, with an average ~mid-$30s.
"GMRE's fundamentals have bottomed and are improving – occupancy is strong, same-store NOI growing ~3%, and the balance sheet risk is largely addressed. The 9% dividend is secure and extremely attractive in the REIT space. Trading at ~7x FFO and ~0.75x NAV, GMRE is deeply undervalued given its portfolio quality and tenant diversification. With a new CEO focused on maximizing value, there are catalysts ahead (potential asset sales, buybacks, or a strategic merger) that could unlock NAV. Even without that, as interest rates eventually ease, yield-focused investors will flock back, compressing GMRE's yield to a more normalized ~7-8%, which implies ~20-30% price upside."
"GMRE remains a risky small-cap REIT. Its leverage is high, and its growth prospects are limited in a high-rate world. The recent dividend cut was necessary but also evidences prior missteps and hasn't translated into growth – AFFO is just treading water. The secondary market assets and some weaker tenants mean GMRE should trade at a higher cap rate/yield than blue-chip peers; a 9-10% yield may be the 'new normal' given elevated treasury yields, which caps the stock around low-$30s. There's also the possibility of further tenant issues. Without a clear growth engine, GMRE is more of a bond substitute."
We assess GMRE's valuation using multiple approaches: current trading metrics relative to peers, an intrinsic NAV estimate, and a simplified discounted cash flow/yield analysis.
GMRE's stock (at ~$33.00 as of this report) trades at the following key multiples:
These metrics suggest GMRE is valued at a substantial discount to peers. If GMRE were valued inline with the peer average P/FFO (~10×), the stock would trade around $45 – 20-30% above current levels.
NAV per share represents the fair value of GMRE's assets minus liabilities, on a per-share basis.
Our NAV estimate range is approximately $41–$49, with a midpoint about $45 per share. At $33, GMRE trades at ~0.74× NAV (using $45 mid). That's a 26% discount to NAV.
| Valuation Method | Intrinsic Value | Notes |
|---|---|---|
| Net Asset Value (NAV) per share | ~$45 (range $41–$49) | Based on ~$115M NOI at ~7.5% cap = $1.53B asset value, minus debt+pref |
| Price/FFO Relative (peer avg 10×) | ~$45 | GMRE at 10× $4.50 FFO = $45. At 8× = $36; at 9× = $40. |
| Dividend Yield Target (7.5–8.0%) | $37.50 – $40.00 | $3.00 dividend at 8.0% yield = $37.50; at 7.5% = $40.00 |
| DDM (0-2% growth, 9-10% req.) | $37 – $43 | Assuming 0% long-term growth, 8% req. gives $37.5 |
| Analyst Consensus PT | ~$35 (avg) | Updated analysts range mid-$30s to $41 |
By most measures, GMRE appears undervalued relative to its fundamentals. It trades at a deep discount to NAV (~25-30%) and sports a high, covered yield that exceeds peers by a large margin. Considering all approaches, we would place GMRE's fair value around $40 per share, which equates to roughly 8.8× 2025E AFFO and a dividend yield of 7.5%. The current price ~$33 is roughly 18% below this fair value, indicating undervaluation.
The dividend is a central component of GMRE's investment appeal, given the stock's high yield.
GMRE has paid regular quarterly dividends since its 2016 IPO. For several years, the dividend was held steady with modest growth early on:
| Year | Dividend/Share (Annual) | FFO/Share | AFFO/Share | FFO Payout | AFFO Payout |
|---|---|---|---|---|---|
| 2019 | $0.82 | $0.92 | $0.98 | 89% | 84% |
| 2020 | $0.82 | $0.92 | $0.97 | 89% | 85% |
| 2021 | $0.82 | $0.92 | $0.98 | 89% | 84% |
| 2022 | $0.82 | $0.92 | $0.98 | 89% | 84% |
| 2023 | $0.82 | $0.83 (est) | $0.91 | ~99% | ~90% |
| 2024 | $0.82 | $0.75 | $0.89 | 109% | 92% |
| 2025 (est) | $3.30 (post-split) | ~$3.00 | ~$4.55 | ~110% | ~73% |
| 2026 (proj) | $3.00 | ~$3.05 | ~$4.60 | ~98% | ~65% |
Given the improved coverage, GMRE's dividend appears sustainable under current operating conditions:
| REIT | Dividend Yield | 2025E Payout (AFFO) | Dividend Growth (5yr) | Notes |
|---|---|---|---|---|
| GMRE | 9.2% | ~66% AFFO | -27% cut in 2025 | Cut in 2025; now well-covered, likely flat near-term |
| Physicians Realty (DOC) | ~6.8% | ~85% of FFO | +0% (flat since 2017) | Steady dividend but no growth |
| Healthcare Realty (HR) | ~7.3% | ~73% of FFO | +1% 5yr CAGR | Maintained through merger |
| Community Healthcare (CHCT) | 13.5% | ~102% of AFFO | +8% 5yr CAGR | High yield but payout unsustainable; at risk of cut |
| Medical Properties (MPW) | ~6.0% | ~30% of FFO | -60% from peak | Major cut in 2023; now low payout |
Near-term (2024-2025), GMRE will likely hold the dividend at $0.75/quarter ($3.00/year). Management signaled this by declaring Q4 2025 at $0.75. If AFFO grows as projected modestly, payout ratio will gradually fall into the low 60s%. That could open the door to small dividend hikes after a period of stability. Possibly, by late 2026 or 2027, GMRE could consider resuming token increases, say 2-3% annually.
Taking a holistic view of Global Medical REIT's fundamentals, portfolio, management, and financials, we assign an overall quality rating of to GMRE. This equates to an above-average but not top-tier quality REIT, reflecting a mix of solid strengths and some notable weaknesses.
| Category | Grade | Assessment |
|---|---|---|
| Property/Portfolio Quality | B+ | Good properties, not Class A urban, but essential and high-occupancy |
| Tenant Quality/Diversity | B | Many strong tenants, some weaker; diversification adequate (no tenant >7%) |
| Management & Governance | B+ | Experienced, shareholder-aligned, making smart moves |
| Financial Strength | B | Solidly managed but moderately high leverage, no IG rating |
| Earnings Stability & Growth | B- | Cash flows stable, but growth has been flat; expects modest growth resumption |
Given the quality assessment, GMRE is best suited for income-oriented investors who seek high current yield with moderate risk. An ideal investor is someone comfortable with mid-cap REITs and looking for reliable dividends, perhaps a retiree or income fund manager who wants healthcare exposure without paying a low yield for the big names. GMRE could also appeal to value investors in the REIT space – those who look for quality improvements that the market hasn't fully priced yet.
Also, an investor with a medium to long-term horizon (3-5+ years) is ideal – to ride out any near-term volatility and allow the undervaluation to correct as GMRE continues to perform.
In conclusion, we regard GMRE as a good-quality REIT with a strong income profile and competent management, offset by its small scale and lower growth. It earns a solid "B" for overall quality, indicating we view it as a reliable, income-producing REIT that is a notch below the highest tier largely due to structural factors (size, leverage) rather than fundamental flaws.
We recommend a Buy rating on Global Medical REIT for investors seeking high current income and moderate capital appreciation potential. GMRE's recent strategic actions have de-risked the story, and at the current ~$33 share price (9.2% yield), the stock offers an attractive entry point.
GMRE presents a compelling 2-part return profile: (1) A well-covered 9% dividend yield providing substantial immediate income, and (2) Potential 20%+ upside as the stock's valuation normalizes (closing some of the discount to NAV and peer multiples). The company's strong occupancy, diversified tenant base, and extended debt maturities underpin stable cash flows, while its prudent dividend reset has positioned it for future growth and improved investor confidence.
This recommendation is suited for income-oriented investors with a medium-term horizon (2+ years). The strategy can appeal to:
Action: Buy GMRE at ~$33, target price $40 (12-mo), secondary target $45 (24-mo), stop $28. Enjoy the ~9% yield as you wait, and look to harvest gains as the market revalues this underappreciated high-yield REIT.